Axa S.A. Has $768,000 Holdings in Kenvue Inc. (NYSE:KVUE)

AXA S.A. raised its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 75.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,954 shares of the company's stock after buying an additional 15,479 shares during the quarter. AXA S.A.'s holdings in Kenvue were worth $768,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Norges Bank acquired a new position in shares of Kenvue in the 4th quarter valued at $521,348,000. Franklin Resources Inc. boosted its holdings in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after buying an additional 8,211,748 shares in the last quarter. Finally, Boston Partners increased its holdings in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after purchasing an additional 6,366,097 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE traded down $0.34 during midday trading on Tuesday, hitting $23.66. 17,775,521 shares of the stock were exchanged, compared to its average volume of 17,104,410. The business has a 50-day moving average price of $23.14 and a two-hundred day moving average price of $22.56. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $45.40 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company's revenue was down 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KVUE shares. Citigroup boosted their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research report on Friday. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Canaccord Genuity Group lifted their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Finally, UBS Group upped their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.